This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Shock/trauma	Type I interferon receptor 1 (IFNAR1)	<p>Studies in mice suggest that inhibiting IFNAR1 could help prevent systemic inflammatory reactions and shock associated with tumor necrosis factor (TNF)-based cancer therapies. In mice receiving TNF-targeted therapy, <i>Ifnar1</i> knockout reduced levels of proinflammatory cytokines and inflammation-mediated bowel damage compared with <i>Ifnar1</i> expression. Next steps include identifying IFNAR1 antagonists.</p> <p>At least four companies have TNF-based cancer therapeutics in clinical and preclinical testing.</p> <p>SciBX 2(34); doi:10.1038/scibx.2009.1318 Published online Sept. 3, 2009</p>	Patent and licensing status unavailable	<p>Huys, L. <i>et al. J. Exp. Med.</i>; published online Aug. 17, 2009; doi:10.1084/jem.20090213</p> <p>Contact: Claude Libert, Ghent University, Ghent, Belgium e-mail: Claude.Libert@UGent.be</p>